Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D06TZT
|
|||
Former ID |
DIB010437
|
|||
Drug Name |
RIPISARTAN
|
|||
Synonyms |
Ripisartan; UP-269-6; 5-Methyl-7-propyl-8-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-1,2,4-triazolo[1,5-c]pyrimidin-2(3H)-one
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Hypertension [ICD-11: BA00-BA04; ICD-9: 401] | Discontinued in Phase 2 | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C23H22N8O
|
|||
Canonical SMILES |
CCCC1=C(C2=NC(=O)NN2C(=N1)C)CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5
|
|||
InChI |
1S/C23H22N8O/c1-3-6-20-19(22-25-23(32)28-31(22)14(2)24-20)13-15-9-11-16(12-10-15)17-7-4-5-8-18(17)21-26-29-30-27-21/h4-5,7-12H,3,6,13H2,1-2H3,(H,28,32)(H,26,27,29,30)
|
|||
InChIKey |
OLJAPHMBAMBVKL-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 148504-51-2
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Angiotensin II receptor type-1 (AGTR1) | Target Info | Antagonist | [2], [3] |
KEGG Pathway | Calcium signaling pathway | |||
cGMP-PKG signaling pathway | ||||
Neuroactive ligand-receptor interaction | ||||
Adrenergic signaling in cardiomyocytes | ||||
Vascular smooth muscle contraction | ||||
Renin-angiotensin system | ||||
Renin secretion | ||||
Pathways in cancer | ||||
NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
Panther Pathway | Angiotensin II-stimulated signaling through G proteins and beta-arrestin | |||
Pathwhiz Pathway | Angiotensin Metabolism | |||
Muscle/Heart Contraction | ||||
Pathway Interaction Database | Arf6 trafficking events | |||
Arf6 signaling events | ||||
Angiopoietin receptor Tie2-mediated signaling | ||||
Reactome | Peptide ligand-binding receptors | |||
G alpha (q) signalling events | ||||
WikiPathways | ACE Inhibitor Pathway | |||
GPCRs, Class A Rhodopsin-like | ||||
Gastrin-CREB signalling pathway via PKC and MAPK | ||||
Peptide GPCRs | ||||
Allograft Rejection | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004530) | |||
REF 2 | In vitro pharmacological characterization of UP 269-6, a novel nonpeptide angiotensin II receptor antagonist. Fundam Clin Pharmacol. 1995;9(2):119-28. | |||
REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.